Compared with the latest generation of targeted drugs, immunotherapy has the potential to fight many kinds of cancer. However, although currently available immunotherapy methods, such as CAR-T and TCT-T, have proven very successful in treating leukemia, they have so far proven less effective in treating other cancers, such as mutant solid tumors.
We are currently recruiting researchers specializing in tumor biology, immunology, molecular biology and related fields. Based on our recombinant protein drug technology, we aim to develop a new generation cell immunotherapy platform that can target multiple cancers, especially solid tumors and other types of critical disease.
Cell Isolation & Selection
In recent years, cell therapy has shown tremendous potential in fields such as stem cell research and immunotherapy. However, the processes involved in these cell therapies, including cell collection, isolation, DNA transfection, cell proliferation, selection and reinfusion, involve intensive manual operations. Therefore, the standardization of the processes for creating cell products for these therapies is a big challenge that can meet an emerging global demand.
EurekaBio creatively combines automation technology with life science technology. Our goal is to provide highly automated prescience for stable, effective and personalized cell therapy solutions.
Stable Cell Lines
Using mammalian cell lines as the expression system, the recombinant protein has optimum folding and post transcriptional modification, with higher biological activity, which offers significant benefits for life science research and drug development purposes.
We have developed multiple mammalian cell lines that have a high expression of recombinant proteins. These proteins cover most of the cytokines and chemokines in stem cell therapy and cancer immunotherapy. Besides research grade recombinant proteins, we also have recombinant protein drug projects, including rhNGF, rhFSH and rhBMP2. Our other services include recombinant protein drugs, cell line constructions, and lentivirus vector systems design.
Join us, be part of our interesting and diverse team. You can make an impact here and we can change the world together.